Supplier to Physiotherapists, General Public, the NHS & Armed Forces

Cutaneous Lymphoma, An Issue of Dermatologic Clinics

Not rated yet
0
The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology.  In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL.  Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists,  specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists.
Some of the topics, written by the word's top experts in this disease, are:  Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas;  in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant;  Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
51   – Reward points
Availability: MD - Manufactured on demand
    • 20% off
    £63.99, save £12.80
  • £51.19
Qty:  
  • Shipping info

    Our publishing partner, Elsevier, maintains a flat fee for shipping. Books are delivered in the UK via DHL and will require a signature upon delivery.

    The standard delivery time within the UK is 2 working days from the date of invoice.

    Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

    At this time we only ship Elsevier book orders to addresses within the UK.

    Brexit: We have been informed that some couriers are now charging additional fees for importing from the UK into the EU. The customer is responsible for the payment of any import duties that are in addition to the shipping costs already charged.

  • Payment methods

    logos-payments-tab_1.png

The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology.  In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL.  Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists,  specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists.
Some of the topics, written by the word's top experts in this disease, are:  Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas;  in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant;  Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
    • SKU
      9780323400824
    • UPC/ISBN
      9780323400824
    • Stock Last Checked
      Mar 29, 2024
  • Manufacturer
    Elsevier
  • Publication Date
    Oct 14, 2015

Your Elsevier book orders are actioned within 48hrs during the working week. If any one item in your purchase is delayed we will send you what is in stock and will send on the remainder as soon as it arrives. This is provided at no additional shipping cost to you. Stock availability levels are updated on a daily basis.  We ship directly from a UK warehouse.

Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

Shipping Costs

We currently maintain a flat fee structure for shipping book titles from Elsevier. Buy as many Elsevier titles as you like the we will still charge you the same single item shipping fee.

Overview Delivery Methods

Books are delivered in the UK via DHL and will require a signature upon delivery.

Deliveries within the UK

  • The standard delivery time within the UK is 2 working days from the date of invoice.
  • Print on demand titles take 3-5 working days.

Where is my order? Order Tracking

To find out more information about your order, select from the relevant options below:

Deliveries to the UK and UK shippers

Your order should be delivered to you/your shipper within 2-3 working days.

To track any deliveries using DPD, click here.

If your order is for a print on demand title, your delivery time will be longer, please allow an extra 3-5 working days.

Customer reviews
There are no comments yet. Be the first to leave a comment
Please sign in to add review

We accept the following payment methods: